GlassScriptPhysician profile
Vandana K Soni
NPI 1316038730
$1,100.16
in general payments reported to CMS, 2019-2025
21 companies · $145 in 2025
The $145 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $525 · 2020: $300 · 2021: $99.04 · 2022: $11.92 · 2023: $18.41 · 2025: $145.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $164.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $163.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $168.51 | 2019-2020 | |
| Eisai INC. | $145.32 | 2025 | |
| Allergan, INC. | $99.17 | 2019-2022 | |
| Acadia Pharmaceuticals INC | $95.70 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $79.97 | 2019-2020 | |
| Biohaven Pharmaceuticals, INC. | $70.96 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $54.04 | 2019-2020 | |
| Avanir Pharmaceuticals, INC. | $48.24 | 2019 | |
| Ucb, INC. | $45.18 | 2019-2020 | |
| Zyla Life Sciences, INC. | $41.19 | 2019 | |
| Neurocrine Biosciences, INC. | $36.68 | 2020 | |
| Amgen INC. | $35.38 | 2019 | |
| Lilly USA, LLC | $29.89 | 2019 | |
| Bausch Health US, LLC | $22.65 | 2020 | |
| Adamas Pharmaceuticals, INC. | $20.13 | 2020 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Assertio Therapeutics, INC. | $19.76 | 2019 | |
| Genzyme Corporation | $19.52 | 2020 | |
| Acorda Therapeutics, INC | $18.63 | 2019 | |
| Pfizer INC. | $18.41 | 2023 | |
| Biogen, INC. | $16.58 | 2020 | |
| Currax Pharmaceuticals LLC | $14.25 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vandana Soni listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.